Clinical Trial Update: Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes ongoing Phase 1/2 evaluation of NGM707 as a monotherapy and in combination with pembrolizumab in advanced or metastatic sol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Glioblastoma
• Melanoma
• Mesothelioma
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Renal Cell Carcinoma

Drugs mentioned

• NGM707 (NGM707)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Mesothelioma, Glioblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING